| abstract |
Herein, a newly identified B7 family member is disclosed, which functions as a counter-receptor, NKp30, for the NK cell YAG receptor. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 and NKp30 as well as related screening methods are disclosed. Further, the present application discloses an antibody-drug conjugate comprising an anti-ZB7H6 antibody, as well as an anti-ZB7H6 antibody conjugated to a therapeutic agent, an antibody and an antibody-drug conjugate thereof used for expressing a therapeutic effect on zB7H6-expressing cells / RTI > |